Cytochroma cytochroma.com


Public lists: Pharma Startups (4732)

Cytochroma is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD. The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stages of development. In January 2013, Cytochroma...Show all

Cytochroma is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products to treat and prevent the clinical consequences of vitamin D insufficiency and SHPT associated with CKD. The Company specializes in dev...Show all

Company (Acquired)

Phone: 905-479-5306

Fax:

100 Allstate Parkway
Suite 600
Markham, L3R 6H3
Ontario, Canada

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cytochroma $24.4M Jan 10, 2013
See all 32 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cytochroma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 11 investors

Competitors

Company Status Description Investors

Intarcia Therapeutics

Boston, Massachusetts, United States
Alive / ActiveIntarcia Therapeutics is a biopharmaceutical company developing therapies to ensure the best treatment outcome by optimizing patient convenience and adherence. Intarcia is addressing challenging diseases that require long-term chronic therapy by enhancing efficacy and reducing the burden therapies often place on the patient's life. Intarcia's drug development expertise and competitive edge is demonstrated by its ability to stabilize macromolecules and to deliver them in a constant and consistent...Show allLogin to see details

Santarus

San Diego, California, United States
AcquiredSantarus is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the prevention and treatment of gastrointestinal diseases and disorders. The company's primary business strategy is to develop and market proprietary products with new formulations, enhanced delivery systems or expanded indications that are based on currently marketed products or compounds that have clinically demonstrated safety and efficacy.Login to see details
See all 32 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Metal compounds mixed or sulphated, as phosphate binders Oct 28, 2013 Jan 26, 2016 Patent
Mixed metal compound Mar 24, 2014 Jun 30, 2015 Patent
Low-calcemic 16,23-diene 25-oxime analogs of 1α,25-dihydroxy vitamin d Apr 25, 2006 Dec 09, 2014 Patent
Methods and compounds for vitamin d therapy Apr 25, 2008 Nov 26, 2013 Patent
Metal compounds, mixed or sulphated, as phosphate binders Jul 01, 2010 Oct 29, 2013 Patent
See all 13 patents